## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.63 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-5.2% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($97.42)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. RVTY: Life sciences, software, and diagnostics show growth, with China stabilizing and margins set to improve**
- Source: TradingView | 20251202T180736 | Bullish | Relevance: 100%
- Revvity (RVTY) is experiencing increased activity in life sciences and instrumentation, with strong growth driven by software and AI initiatives. Immunodiagnostics and newborn screening are expanding, and the diagnostics sector in China is stabilizing after policy changes. The company anticipates positive margin and revenue outlooks for 2026.

**2. Jim Cramer Recently Discussed These 9 Stocks**
- Source: Insider Monkey | 20251202T232300 | Bullish | Relevance: 99%
- Jim Cramer recently discussed nine stocks, highlighting Revvity, Inc. (NYSE:RVTY) due to its cheap valuation despite past disappointing results. Cramer noted Revvity's improved performance in October and raised full-year earnings forecast, positioning it as the most affordable in its group. The company provides essential instruments, reagents, software, and sequencing services for genetic testing and research.

**3. The Bull Case For Danaher (DHR) Could Change Following New Fiduciary-Duty Probe Into Its Boardroom**
- Source: Simply Wall Street | 20251203T084020 | Neutral | Relevance: 62%
- Halper Sadeh LLC has launched an investigation into potential breaches of fiduciary duty by certain Danaher Corporation officers and directors. This probe could impact Danaher's investment narrative by scrutinizing its governance and board oversight, especially concerning capital allocation decisions like share repurchases. While the near-term demand outlook remains stable, the investigation highlights the importance of accountability alongside the company's growth ambitions.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.63 indicates undervaluation relative to growth. Forward P/E 19.5x stretched relative to 8% growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.2B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 7.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.63 |
| Forward P/E | 19.5 |
| Current P/E | 21.0 |
| YoY Growth | 7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 10.1% to 4.9% (-5.2% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 86th percentile. MRS_5 (-0.7%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 6.9% shows strong absolute momentum above own 20MA. Outperforming sector by 5.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.81), confirming momentum. OFD pattern: =DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.91% (CS: 86) | Strong |
| RSI_14 | 64.6 | Neutral |
| MACD Histogram | 0.81 | Bullish |
| vs SMA20 | 1.069x | Above |
| vs SMA50 | 1.100x | Above |
| vs SMA200 | 1.078x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $103.26
- **Stop Loss:** $97.42 (5.7% risk)
- **Target:** $114.94 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 162
- **Position Value:** $16,728.12
- **Portfolio %:** 16.73%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*